The landscape of molecular design has shift Peptide stapling and cyclic peptide design. 18F-labelling for advanced applications. SAR generation and PK optimisation for peptide-based small molecules.Read more ed dramatically with the emergence of cyclic peptide PROTACs. As someone deeply interested in the evolution of biochemical tools, I have found that the transition from static, small-molecule inhibitors to dynamic, heterobifunctional degradation systems represents a paradigm shift in how we interact with cellular machin Unlike small molecules,cyclic peptides can offer a larger surface area for interaction with their protein targets, potentially leading to more specific and Read more ery.
Understanding the Core Mechanism: What is a PROTAC?
At its most fundamental level, Proteolysis Targeting Chimeras (PROTACs) are bivalent molecules that consist of two ligand warheads. One ligand binds to a specific protein of interest (POI), while the other recruits an E3 ubiquitin ligase. This ingenious design co-opts the cell's natural ubiquitin-proteasome system to induce the selective degradation of the target protein.
While early PROTACs often relied on small molecules, they frequently faced challenges regarding membrane permeability and solubility. This is where the integration of peptide technology becomes a game-changer. By leveraging t by LS Newton·2025·Cited by 23—We have designed and characterised antiviralPROteolysis TArgeting Chimeras (PROTACs) targeting the human protein cyclophilin A (CypA), a host cofactor for Read more he structural rigidity of cyclic peptides, researchers are overcoming previous limitations, creating molecules that are more robust and capable of engaging challenging protein surfaces.
The Advantages of Cyclic Peptide Design
In my observation of recent laboratory advancements, cyclic peptides offer a larger surface area for interaction with their protein targets compared to traditional small molecules. This increased surface contact is essential for achieving higher specifi 2 days ago—The development ofcyclic peptide-based PROTACsfurther enhances stability and offers improved anti-PD-L1 activity. In conclusion, the Read more city.
A particularly exciting area is peptide stapling and cyclic peptide design. By constructing an N-terminal lactam cycle or utilizing disulfide bridges, scientists can significantly improve proteolytic stability and cell penetration. These designed penetrated peptide-based PROTACs address one of the primary hurdles in the field: the ability to traverse biological membranes effectively without sacrificing the structural integrity required for target binding.
Key Modalities by Y Dai·2020·Cited by 46—Here, wedesigned penetrated peptide-based PROTACsby constructing an N-terminal lactam cyclic to improve proteolytic stability and cell penetration.Read more and Research Applications
My interest in this field led me to explore several noteworthy implementations of this technology:
* Disulfide-bridged cyclic peptide PROTAC: These molecules have demonstrated improved stability and enhanced anti-PD-L1 activity, showcasing the potential of structural modification.
* BPD as a peptide-based PROTAC: This specific degrader has been shown to successfully target proteins like BRCA2, effectively accumulating in cellular models to modulate homologous recombination.
* Nanodelivery Systems: I have been following the development of cyclic peptide-derived PROTAC nanodelivery systems, which use enzyme-responsive triggers to enhance the precision of the degradation process.
* PROTAC β-catenin degraders: By coupling specific peptides with VHL ligands, researchers have achieved durable degradation, proving that these tools are highly effective for complex pathways.
Why This Matters for Future Discovery
PROTACs have demonstrated significant potential in overcoming drug resistance and targeting proteins that were previously considered "undruggable." Because PROTAC is a new type of treatmen Jan 1, 2025—PDF | Targeted degraders andcyclic peptidesare both emerging therapeutic modalities. This review describes recent efforts to combine these t modality, it allows for the dynamic degradation of intracellular or nuclear proteins rather than simple inhibition. This approach is fundamentally different from traditional pharmacology.
Whether we are looking at macrocyclic peptides as a robust scaffold or exploring the nuances of peptide PROTAC architecture—which typically consists of a target protein binding peptide (TBP) and a linker peptide (LP)—the field is moving toward a more sophisticated era of biochemical engineering.
In my view, the integration of cyclic peptide-based PROTACs into standard research workflows will continue to expand our ability to probe biological systems with unprecedented precision. As we continue to refine Sep 15, 2025—BPD is a peptide-based PROTACthat effectively degrades BRCA2, selectively accumulates in tumor cells, reduces homologous recombination these chimeric strategies, the ability to selectively remove proteins will undoubtedly provide deeper insights into cellular function, far beyond what simple small-molecule inhibitors could ever ach Peptide-Based PROTACs: Transitioning from Static Paradigm ieve.